Program
TyboWe® Adalimumab Injection
Its studies are mostly in Crohn Disease · Uveitis, led by Sino Biopharmaceutical.
Furthest: phase 4, since Jun 17, 20262 company-led studies, 2 open or runningNext primary completion: Feb 2028 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 22 open or running | phase 4since Jun 17, 2026 | Jun 17, 2026 | Feb 2028phase 4 · NCT07663331 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 17, 2026First studies: 2 phase 4 studiesFirst studyNCT07663526, NCT07663331
Ahead
- Feb 2028Primary completion: phase 4 study in Adult Non-infectious UveitisNCT07663331
- Dec 2028Primary completion: phase 4 study in Crohn DiseaseNCT07663526
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07663331Adult Non-infectious Uveitis · China | 4 | Recruiting | Feb 2028 | 30 |
| NCT07663526Crohn Disease · China | 4 | Recruiting | Dec 2028 | 50 |
How it is read
Names in the registry
- “TyboWe® Adalimumab Injection”, 2 entries
Conditions, from the studies’ own filings
- Crohn Disease, 1 study
- Uveitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.